Login / Signup

Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.

Daniela V CastroSweta R PrajapatiMatthew I FengElyse H ChanKyle O LeeTrishita PaulIshaan SehgalJalen PatelXiaochen LiZeynep B ZenginHedyeh EbrahimiAmeish GovindarajanLuis MezaBenjamin D MercierNeal S ChawlaNazli DizmanErrol J PhilipJoAnn HsuCristiane D BergerotAlex Chehrazi-RaffleAdam G RockSandy LiuAbhishek TripathiTanya B DorffSumanta Kumar Pal
Published in: BJU international (2023)
A substantial proportion of RCC trials utilize restrictive eligibility criteria, excluding patients with fairly prevalent comorbidities. Implementing the ASCO-FCR recommendations will ensure resulting data is more inclusive and aligned with patient populations in the real-world.
Keyphrases
  • renal cell carcinoma
  • electronic health record
  • case report
  • big data
  • clinical practice
  • stem cells
  • genetic diversity
  • cell therapy
  • bone marrow
  • drug induced
  • replacement therapy